Agnieszka Stelmaszyk

Agnieszka Stelmaszyk

Auto-generated profile, based on publicly available information

Agnieszka Stelmaszyk

Department of Pharmacology, Poznan University of Medical Sciences, Poznan, Poland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ASAgnieszka Stelmaszyk
Agnieszka Stelmaszyk
PMPrzemysław Mikołajczak
Przemysław Mikołajczak
MDMarzena Dworacka
Marzena Dworacka

1 September 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MDMarzena Dworacka
Marzena Dworacka
SISaule Iskakova
Saule Iskakova
AWAnna Wesołowska
Anna Wesołowska
GZGulmira Zharmakhanova
Gulmira Zharmakhanova
ASAgnieszka Stelmaszyk
Agnieszka Stelmaszyk
GDGrzegorz Dworacki
Grzegorz Dworacki

20 July 2018 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
PDF file
ASAgnieszka Stelmaszyk
Agnieszka Stelmaszyk
AWAnna Wesołowska
Anna Wesołowska
KPKarolina Pomieczyńska
Karolina Pomieczyńska
SISaule Iskakova
Saule Iskakova
MFMagdalena Frydrychowicz
Magdalena Frydrychowicz
MDMarzena Dworacka
Marzena Dworacka
Introduction: Cardiovascular risk in the course of diabetes depends greatly on glycemic variability which is even more significant than chronic hyperglycemia. Optimal management of diabetes involves a multidisciplinary approach focused in particular on decreasing the risk of atherosclerosis. Therefore, our purpose was to evaluate the impact of dapagliflozin on glucose excursions and related proatherogenic changes in the aortic wall. Methods and materials Animal model of type 2 diabetes rich-fat/STZ rats was used. Wistar rats were randomized into 3 groups: dapagliflozin-treated with glucose excursions, placebo-treated with glucose excursions and placebo-treated with stable diabetes. Dapagliflozin was administered once a day, 1 mg/kg, for 8 consecutive weeks. Glucose levels were measured twice a week at fasting and postprandially. The samples of aortas were taken for histopathological and immunochemistry examinations at the end of the experiment. The derangement in the aortic wall and the distribution of CD68+ cells in the aorta were considered early signs of atherosclerosis. Results: Dapagliflozin reduced glucose excursion to the level characteristic for stable, well-controlled diabetes. It was related to a significant decrease in histopathological changes which were observed in the placebo-treated rats with glucose variability. Dapagliflozin significantly reduced also the accumulation of CD68+ macrophages in the aortic adventitia. Conclusion: Dapagliflozin provides not only mere beneficial regulation of metabolic status with the depletion of glucose variability, but is also helpful in the prevention of early atherosclerosis related to the course of diabetes type 2.

21 May 2018 in Clinical Diabetology
Verified
Journal Article
Open access
PDF file
ASAgnieszka Stelmaszyk
Agnieszka Stelmaszyk
MDMarzena Dworacka
Marzena Dworacka
The level of expression of certain genes modifying the phenotype may affect the progression of diabetes mellitus and its complications. Gene expression is controlled by epigenetic modifications, influenced by intracellular and environmental factors, e.g. nutrition model and physical activity. These modifications appear throughout whole life, from conception until the time of death, and they are closely dependent on cell differentiation, DNA repair and cellular stress. Hopefully, the knowledge of epigenetics might be used in the future as an element of personalized treatment of diabetes. The following article aims to review the most important mechanisms of epigenetic modifications in context of pathogenesis and pathophysiology of type 2 diabetes mellitus. The level of expression of certain genes modifying the phenotype may affect the progression of diabetes mellitus and its complications. Gene expression is controlled by epigenetic modifications, influenced by intracellular and environmental factors, e.g. nutrition model and physical activity. These modifications appear throughout whole life, from conception until the time of death, and they are closely dependent on cell differentiation, DNA repair and cellular stress. Hopefully, the knowledge of epigenetics might be used in the future as an element of personalized treatment of diabetes. The following article aims to review the most important mechanisms of epigenetic modifications in context of pathogenesis and pathophysiology of type 2 diabetes mellitus.

1 September 2015 in Pharmacological Reports
Verified
Journal Article
Closed access
HWHanna Winiarska
Hanna Winiarska
AWAnna Wesołowska
Anna Wesołowska
SISaule Iskakova
Saule Iskakova
GZGulmira Zharmankhanova
Gulmira Zharmankhanova
OUOlzhas Urazayev
Olzhas Urazayev
MDMarzena Dworacka
Marzena Dworacka

29 December 2025 in Journal of Medical Science
Verified
Journal Article
Open access
AWAnna Wesołowska
Anna Wesołowska
MOMarcin Ożarowski
Marcin Ożarowski
Przemysław Łukasz MikołajczakPrzemysław Łukasz Mikołajczak
Przemysław Łukasz Mikołajczak
ASAgnieszka Stelmaszyk
Agnieszka Stelmaszyk
AMAnna Maliszewska-Dworacka
Anna Maliszewska-Dworacka
MDMarzena Dworacka
Marzena Dworacka
Aim. To investigate the possible effects of Passiflora extract on VEGF and TGF-β1 mRNA expression – growth factors closely related to the development of diabetes in the cardiovascular system. Material and methods. The animal model of type 2 diabetes, rich-fat/STZ Wistar rats, was used. Animals were randomised into four groups: Passiflora-treated type 2 diabetes mellitus model group; metformin-treated type 2 diabetes mellitus model group; placebo-treated type 2 diabetes mellitus model group; and placebo-treated non-diabetic control group. Passiflora incarnata leaf extract was administered orally once daily for eight consecutive weeks. mRNA VEGF, VEGF-R1, VEGF-R2 and TGF-β1 expression were measured in the myocardium and the aorta. Results. Passiflora incarnata extract increases VEGF and VEGFR2 mRNA expression in the myocardium of rats with type 2 diabetes and decreases expression in the aortal wall. The expression of TGF-β1 mRNA in both the myocardium and the aorta is reduced in Passiflora incarnata-treated rats with diabetes. Most observed effects are independent of the animals' current metabolic status. Conclusions. The current data provide novel findings on the beneficial effects of Passiflora extract on the myocardium in the context of type 2 diabetes, potentially through mechanisms involving VEGF and TGF-β1. However, the significance of the impact of Passiflora extract on the aorta wall via VEGF and TGF-β1 is uncertain.